Atreides Management LP Makes New Investment in Synopsys, Inc. $SNPS

Atreides Management LP bought a new stake in shares of Synopsys, Inc. (NASDAQ:SNPS) in the third quarter, Holdings Channel reports. The fund bought 38,876 shares of the semiconductor company’s stock, valued at approximately $19,181,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Brighton Jones LLC lifted its holdings in shares of Synopsys by 5.7% in the fourth quarter. Brighton Jones LLC now owns 921 shares of the semiconductor company’s stock worth $447,000 after buying an additional 50 shares in the last quarter. Integrated Wealth Concepts LLC grew its stake in Synopsys by 11.6% during the first quarter. Integrated Wealth Concepts LLC now owns 760 shares of the semiconductor company’s stock valued at $326,000 after acquiring an additional 79 shares in the last quarter. NewEdge Advisors LLC grew its stake in Synopsys by 15.1% during the first quarter. NewEdge Advisors LLC now owns 3,010 shares of the semiconductor company’s stock valued at $1,291,000 after acquiring an additional 395 shares in the last quarter. PNC Financial Services Group Inc. increased its holdings in Synopsys by 17.1% during the 2nd quarter. PNC Financial Services Group Inc. now owns 32,006 shares of the semiconductor company’s stock worth $16,409,000 after acquiring an additional 4,670 shares during the period. Finally, Banco Bilbao Vizcaya Argentaria S.A. increased its holdings in Synopsys by 47.8% during the 2nd quarter. Banco Bilbao Vizcaya Argentaria S.A. now owns 27,170 shares of the semiconductor company’s stock worth $13,925,000 after acquiring an additional 8,782 shares during the period. 85.47% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have commented on SNPS. The Goldman Sachs Group set a $600.00 price target on shares of Synopsys and gave the company a “buy” rating in a report on Wednesday, February 25th. HSBC cut shares of Synopsys from a “buy” rating to a “hold” rating and set a $455.00 price target on the stock. in a report on Friday, February 20th. Bank of America raised Synopsys from an “underperform” rating to a “neutral” rating and dropped their price objective for the company from $525.00 to $500.00 in a research note on Monday, December 8th. Morgan Stanley restated an “equal weight” rating and set a $480.00 target price (down from $550.00) on shares of Synopsys in a research report on Wednesday, February 25th. Finally, KeyCorp upped their target price on Synopsys from $575.00 to $600.00 and gave the stock an “overweight” rating in a research note on Thursday, December 11th. Eight equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $531.00.

Insider Activity

In other news, CFO Shelagh Glaser sold 3,657 shares of the company’s stock in a transaction dated Friday, December 19th. The stock was sold at an average price of $460.77, for a total value of $1,685,035.89. Following the completion of the transaction, the chief financial officer directly owned 17,842 shares in the company, valued at approximately $8,221,058.34. This represents a 17.01% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Janet Lee sold 250 shares of the stock in a transaction dated Monday, January 12th. The shares were sold at an average price of $530.00, for a total value of $132,500.00. Following the transaction, the insider owned 11,959 shares in the company, valued at $6,338,270. This trade represents a 2.05% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 4,157 shares of company stock valued at $1,945,036. Corporate insiders own 0.56% of the company’s stock.

Synopsys Stock Performance

Synopsys stock opened at $412.63 on Friday. The firm’s fifty day moving average price is $461.93 and its 200-day moving average price is $463.65. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.26 and a current ratio of 1.36. The stock has a market cap of $79.04 billion, a P/E ratio of 64.07, a price-to-earnings-growth ratio of 3.36 and a beta of 1.15. Synopsys, Inc. has a fifty-two week low of $365.74 and a fifty-two week high of $651.73.

Synopsys (NASDAQ:SNPS) last posted its quarterly earnings data on Wednesday, February 25th. The semiconductor company reported $3.77 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.56 by $0.21. The company had revenue of $2.41 billion during the quarter, compared to the consensus estimate of $2.39 billion. Synopsys had a net margin of 13.76% and a return on equity of 6.83%. The firm’s revenue was up 65.6% compared to the same quarter last year. During the same period in the previous year, the firm posted $3.03 EPS. Synopsys has set its FY 2026 guidance at 14.380-14.460 EPS and its Q2 2026 guidance at 3.110-3.170 EPS. On average, equities research analysts expect that Synopsys, Inc. will post 10.64 earnings per share for the current fiscal year.

Synopsys Profile

Synopsys, Inc is a leading provider of electronic design automation (EDA) software and semiconductor intellectual property (IP) used to design, verify and manufacture integrated circuits and complex systems-on-chip (SoCs). Its product portfolio spans tools and technologies for front‑end design and synthesis, simulation and verification, physical implementation and signoff, and design-for-manufacturability, enabling chip designers to move from architecture through tape‑out.

In addition to core EDA offerings, Synopsys supplies a broad set of semiconductor IP building blocks — such as interface, memory and analog/mixed-signal cores — that customers integrate into SoCs to accelerate development.